Last reviewed · How we verify
Ultravate (ulobetasol propionate)
Ultravate (generic name: ulobetasol propionate) is a ulobetasol propionate drug developed by Ranbaxy. It is currently FDA-approved (first approved 1990) for Plaque Psoriasis.
Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation.
Ultravate, also known as halobetasol propionate, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester that acts as a glucocorticoid receptor agonist. It has been studied in clinical trials for conditions such as plaque psoriasis, acne keloidalis nuchae, and healthy subjects, and is available in various topical formulations including ointments and lotions.
At a glance
| Generic name | ulobetasol propionate |
|---|---|
| Sponsor | Ranbaxy |
| Drug class | ulobetasol propionate |
| Target | Glucocorticoid receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1990 |
Mechanism of action
Corticosteroids play role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Approved indications
- Plaque Psoriasis
Common side effects
- stinging or burning
- pustulation
- erythema
- skin atrophy
- leukoderma
- acne
- itching
- secondary infection
- telangiectasia
- urticara
- dry skin
- miliaria
Key clinical trials
- A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310) (PHASE3)
- A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) (PHASE3)
- Duobrii Treatment of Acne Keloidalis Nuchae (AKN) (PHASE3)
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (PHASE4)
- Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids (PHASE2)
- Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultravate CI brief — competitive landscape report
- Ultravate updates RSS · CI watch RSS
- Ranbaxy portfolio CI
Frequently asked questions about Ultravate
What is Ultravate?
How does Ultravate work?
What is Ultravate used for?
Who makes Ultravate?
What is the generic name of Ultravate?
What drug class is Ultravate in?
When was Ultravate approved?
What development phase is Ultravate in?
What are the side effects of Ultravate?
What does Ultravate target?
Related
- Drug class: All ulobetasol propionate drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Ranbaxy — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Plaque Psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing